(Story updated with more IPO news)
NEW YORK ( TheStreet) -- U.S. IPOs could find themselves back in the limelight this year after spending the bulk of 2010 being overshadowed by Asian public offerings.
AcelRx Pharmaceuticals (ACRX) announced on Thursday that ARX-04, its experimental pain relief drug, had positive results in a phase III clinical trial.
Trade-Ideas LLC identified AcelRx Pharmaceuticals (ACRX) as a weak on high relative volume candidate
Trade-Ideas LLC identified AcelRx Pharmaceuticals (ACRX) as a strong on high relative volume candidate
There's a valuable, albeit painful, lesson here in Amicus' blow-up. Biotech CEOs should shut their mouths about regulatory plans until they receive definitive word from the FDA.